Production of mycophenolic acid by Penicillium brevicompactum—A comparison of two methods of optimization

Patel, Gopal; Patil, Mahesh D.; Soni, Surbhi; Khobragade, Taresh P.; Chisti, Yusuf; Banerjee, Uttam Chand

doi:10.1016/j.btre.2016.07.003

Cited by 42 publications

(25 citation statements)

References 30 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Optimum growth conditions for different Penicillium spp. have been reported earlier as at temperatures varying from 25°C-30°C, incubation time ranging from 12 to 15 days and at neutral pH [12][13][14] .…”

Section: Fig 5: Pictorial Representation Of (A) Biomass Produced Undmentioning

confidence: 64%

Untitled

2020

IJPSR

View full text Add to dashboard Cite

There are many pharmaceutically important compounds from Penicillium sp. that made the fungal genera one of the most important sources for the production of bioactive metabolites. As per the results of our previous study, a bioactive metabolite, P5, from Penicillium rubens JGIPR9 had highly promising cytotoxic and anti-cancer potentials. This prompted us to undertake the current study, so as to optimize the culture conditions of this fungal isolate and thereby to enhance its growth, i.e., biomass (response 1) and production of the anticancer metabolite P5 (response 2). Initially, the single factor method was adopted to screen the individual culture conditions that would enhance the responses under the study. The best factors being CdCl 2 , glucose, amino acid concentrate, and beef extract were subjected to Central Composite Design (CCD) to identify the optimal conditions that enhance the responses. The biomass dry weight ranged from 11.9-24.1 g/L and that of P5 concentration ranged from 257-774 mg/L. The optimal conditions were verified experimentally and 3.24-fold and 12.21-fold increase were observed for responses 1 and 2 respectively in comparison to the basal culture conditions.

show abstract

Section: Fig 5: Pictorial Representation Of (A) Biomass Produced Undmentioning

confidence: 64%

Untitled

2020

IJPSR

View full text Add to dashboard Cite

show abstract

“…Patel et al compared between one at a time variation factors and CCD for the production of mycophenolic acid by Penicillum brevicompactum MTCC8010 in a 12-day batch culture. The medium optimization using one-at-a-time variation gave 6 fold greater titer, whereas CCD gave almost 9 fold greater titer compare to the production prior to the optimization [21].…”

Section: Discussionmentioning

confidence: 99%

Statistical Optimization of Culture Conditions for L-Methionine Production by Corynebacterium glutamicum X300

Ganguly¹,

Satapathy²

2017

J Theor Comput Sci

View full text Add to dashboard Cite

“…Secondary metabolites produced by fungi are also drug leads for many immunosuppressants used in related inflammatory disorders such as mycophenolic acid (produced by Penicillium spp.) [281], cyclosporin (produced by Tolipocladium inflatum) [282], and fingolimod (Gilenya TM ) derived from myriocin (produced by Isaria sinclairii) [283]. Many such molecules and metabolites derived from various fungi and macrofungi (mushrooms) with potent anti-inflammatory properties are reviewed elsewhere [284,285].…”

Section: Fungal-derived Anti-inflammatory Drug Leadsmentioning

confidence: 99%

Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products

Yeshi

Ruscher

Hunter

et al. 2020

JCM

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic and life-long disease characterized by gastrointestinal tract inflammation. It is caused by the interplay of the host’s genetic predisposition and immune responses, and various environmental factors. Despite many treatment options, there is no cure for IBD. The increasing incidence and prevalence of IBD and lack of effective long-term treatment options have resulted in a substantial economic burden to the healthcare system worldwide. Biologics targeting inflammatory cytokines initiated a shift from symptomatic control towards objective treatment goals such as mucosal healing. There are seven monoclonal antibody therapies excluding their biosimilars approved by the US Food and Drug Administration for induction and maintenance of clinical remission in IBD. Adverse side effects associated with almost all currently available drugs, especially biologics, is the main challenge in IBD management. Natural products have significant potential as therapeutic agents with an increasing role in health care. Given that natural products display great structural diversity and are relatively easy to modify chemically, they represent ideal scaffolds upon which to generate novel therapeutics. This review focuses on the pathology, currently available treatment options for IBD and associated challenges, and the roles played by natural products in health care. It discusses these natural products within the current biodiscovery research agenda, including the applications of drug discovery techniques and the search for next-generation drugs to treat a plethora of inflammatory diseases, with a major focus on IBD.

show abstract

Production of mycophenolic acid by Penicillium brevicompactum—A comparison of two methods of optimization

Abstract: HighlightsMedium optimization for MPA production using P. brevicompactum by one-factor-at-a-time and CCD methods.CCD afforded a 40% higher MPA titer than one-factor-at-a-time method.The titer was nearly 6-fold higher compared to un-optimized medium.

Cited by 42 publications

References 30 publications

Untitled

Untitled

Statistical Optimization of Culture Conditions for L-Methionine Production by Corynebacterium glutamicum X300

Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products

Contact Info

Product

Resources

About